Loading...

Xenetic Biosciences, Inc.

XBIOWNASDAQ
Healthcare
Biotechnology
$17.54
$-5.40(-23.54%)

Xenetic Biosciences, Inc. (XBIOW) Company Profile & Overview

Explore Xenetic Biosciences, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Xenetic Biosciences, Inc. (XBIOW) Company Profile & Overview

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

SectorHealthcare
IndustryBiotechnology
CEOJames F. Parslow

Contact Information

945 Concord Street, Framingham, NV

Company Facts

4 Employees
IPO DateJul 23, 2019
CountryUS

Frequently Asked Questions

;